Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
89 patients were enrolled.
I · Intervention 중재 / 시술
first-line GA-based therapy, including GA alone or GA in combination with S-1 (GAS)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No treatment-related mortality was found. [CONCLUSION] The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
[BACKGROUND] Pancreatic adenocarcinoma is one of the leading causes of cancer-related mortality.
- 추적기간 10.2 months
APA
Tseng KY, Hsu CY, et al. (2026). Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.. Therapeutic advances in medical oncology, 18, 17588359261420081. https://doi.org/10.1177/17588359261420081
MLA
Tseng KY, et al.. "Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.." Therapeutic advances in medical oncology, vol. 18, 2026, pp. 17588359261420081.
PMID
41883866 ↗
Abstract 한글 요약
[BACKGROUND] Pancreatic adenocarcinoma is one of the leading causes of cancer-related mortality. The median overall survival (OS) of patients with advanced pancreatic ductal adenocarcinoma (PDAC) is less than 1 year. The recent phase III NAPOLI-3 study showed that triplet chemotherapy improved OS compared to the commonly used gemcitabine/nab-paclitaxel (GA) regimen. S-1 is widely used in Asia for the treatment of PDAC, and a combination strategy with S-1 has shown encouraging results in previous studies.
[OBJECTIVES] We aimed to determine whether the addition of S-1 to GA offers more benefits than GA alone as a first-line treatment for advanced PDAC.
[DESIGN] This was a retrospective study of patients with advanced PDAC treated at the Taichung Veterans General Hospital, Taiwan. All patients received first-line GA-based therapy, including GA alone or GA in combination with S-1 (GAS).
[METHODS] Retrospectively reviewed clinical characteristics and outcomes, including the objective response rate (ORR), progression-free survival (PFS), and OS, were compared between the two groups. Some patients underwent genetic testing using the FoundationOne CDx (Foundation Medicine). The effects of the treatment on major genetic alterations were also analyzed.
[RESULTS] Between January 1, 2022, and February 10, 2025, 89 patients were enrolled. Among these, 45 and 44 underwent GA and GAS, respectively. The median follow-up time was 10.2 months. ORR was significantly higher in patients who received GAS than in those who did not (48% vs 18%, = 0.001). GAS showed both significant improvement of PFS (10.0 vs 5.2 months; = 0.004) and OS (not reached vs 8.5 months; = 0.016) compared with GA. Multivariate analysis identified only the treatment regimen as an independent prognostic factor for OS. GAS also improved the survival of patients harboring major genetic alterations. The Grade ⩾3 hematological adverse events were more in GAS, according to the CTCAE, version 5.0. No treatment-related mortality was found.
[CONCLUSION] The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
[OBJECTIVES] We aimed to determine whether the addition of S-1 to GA offers more benefits than GA alone as a first-line treatment for advanced PDAC.
[DESIGN] This was a retrospective study of patients with advanced PDAC treated at the Taichung Veterans General Hospital, Taiwan. All patients received first-line GA-based therapy, including GA alone or GA in combination with S-1 (GAS).
[METHODS] Retrospectively reviewed clinical characteristics and outcomes, including the objective response rate (ORR), progression-free survival (PFS), and OS, were compared between the two groups. Some patients underwent genetic testing using the FoundationOne CDx (Foundation Medicine). The effects of the treatment on major genetic alterations were also analyzed.
[RESULTS] Between January 1, 2022, and February 10, 2025, 89 patients were enrolled. Among these, 45 and 44 underwent GA and GAS, respectively. The median follow-up time was 10.2 months. ORR was significantly higher in patients who received GAS than in those who did not (48% vs 18%, = 0.001). GAS showed both significant improvement of PFS (10.0 vs 5.2 months; = 0.004) and OS (not reached vs 8.5 months; = 0.016) compared with GA. Multivariate analysis identified only the treatment regimen as an independent prognostic factor for OS. GAS also improved the survival of patients harboring major genetic alterations. The Grade ⩾3 hematological adverse events were more in GAS, according to the CTCAE, version 5.0. No treatment-related mortality was found.
[CONCLUSION] The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.
- Carbon ion radiotherapy optimization techniques for pancreatic cancer: accounting for the effect of bowel gas variation.
- Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer.
- Preventive Role and Survival Benefit of Beta Blockers in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies.
- The hematopoietic stem cell MYB enhancer is essential for and recurrently amplified during T cell leukemogenesis.